Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $21.57, but opened at $20.73. Chugai Pharmaceutical shares last traded at $21.8770, with a volume of 8,531 shares trading hands.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CHGCY shares. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

The company has a market capitalization of $71.18 billion, a price-to-earnings ratio of 23.51 and a beta of 0.59. The firm’s 50-day simple moving average is $21.66 and its two-hundred day simple moving average is $24.26.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. On average, analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.